Including mental health in the global health and development agenda

Including mental health in the global health and development agenda

Why are mental disorders and substance use disorders treated so much differently than other health conditions? This is just one of the many questions that the World Bank Group, World Health Organization and other international partners will pose at their upcoming event — Out of the Shadows: Making Mental Health a Global Development Priority — on April 13th -14th ,  as part of the 2016 WBG/IMF Spring Meetings.

If mental health disorders are conditions of the brain, why do we treat these conditions so differently than heart conditions or cancer?   And in doing so, do we realize that this approach ignores all of the evidence that shows us that mental illness is a major disability burden worldwide? If untreated, mental disorders can negatively affect management of common co-occurring diseases, such as tuberculosis and HIV, diabetes, hypertension, cardiovascular disease, and cancer.

For all of these reasons and many more, the WBG-WHO are aiming to put the mental health agenda where it belongs — at the center of global health and development priorities and remove all disparities.

In his sobering and deeply touching memoir, A Common Struggle, former U.S. Congressman Patrick J. Kennedy, shares his personal struggle with mental disorders and substance abuse and unpacks some of the issues surrounding mental health.

In the United States, as well as in countries such as Chile, Colombia and Ghana, where they are trying to push for equality for mental illnesses and addiction treatment, a common barrier to overcome is preexisting conditions clauses that deny health insurance coverage.  And even if this hurdle is overcome, explained Congressman Kennedy, who will deliver a keynote at the event, the next big issue is to determine what is covered, funded, and enforced at the provider level.  And this leads to a whole host of additional questions, such as:

  • Would coverage be offered for common mental illnesses such as depression and anxiety disorders, or just for severe mental illnesses such as schizophrenia, bipolar disorder, and disabling clinical depression?
  • Would addictions be covered?
  • How to select the menu of evidence-based treatments to be offered by service providers at different levels of care, as is commonly done for other health conditions at the community level and on ambulatory clinics, local hospitals or specialized treatment centers?
  • We know that services for mental disorders depend heavily on adequate number of trained health personnel; how do we bridge the gap in their availability?
  • How about drugs, are they going to be brand name or equally effective generics?  Who decides and on what basis?
  • Would there be a mandate for all public and private insurance plans to cover mental health?
  • And how are these services going to be funded and reimbursed, particularly not to perpetuate medical discrimination in the subtle way of high deductibles, copayments, and lifetime limitations in coverage under health insurance arrangements?
  • What strategies can be used to integrate mental health care as part of services delivery platforms that focus on the patient as a whole rather than an aggregation of separate diseases?
  • And even if all these policy and service delivery changes are adopted, would affected persons who need mental healthcare and their families defy the stigma of being seen as “mental ill”” and get services and adhere to prescribed medication and psychotherapies?
  • What can be done to create facilitating workplace environments that help affected people overcome fear of losing a job or health insurance coverage if one were to disclose a mental health affliction and seek mental healthcare when needed?

At the same time that we pose these questions that have both political and financial implications, we also need to explore other “entry points” across sectors to bring mental health out of a centuries-old shadow—from school-based interventions, wellness and health in the workplace programs, initiatives to address the physical and mental health needs of displaced populations, refugees, and persons living in post-conflict, post-natural disasters, epidemics and post-epidemic (e.g., Ebola in West Africa) situations. To that end, we need to build upon social protection and employment initiatives that facilitate the reintegration of affected persons back into their communities as valuable members of society.  Hence, by accepting that mental health is a development challenge, we need to pursue different cross-cutting and multidisciplinary approaches, and funding streams.

We already have the evidence-based medical treatments and support therapies that can help alleviate the silent suffering for so many. Political will and commitment to sustainable funding, improved and scaled up service provision as a right of the population is required.  And besides the human toll, let’s not forget that the social cost of inaction is staggeringly high as measured in terms of broken families, less cohesive and inclusive  communities, labor supply losses, high rates of unemployment among mentally-ill persons, disability costs, absenteeism and reduced productivity at work from unattended depression and anxiety disorders.

Let’s remain optimistic that recent attention and interest on this issue will lead to increased commitments to implementing a global, multisectoral effort to scale up mental health services in primary care and community settings.

The original blog post was written by Patricio V Marquez and Shekhar Saxena and was published in the World Bank Blog blog. 

Smartphone-based CBT aims to reduce hospital readmissions 50%

Smartphone-based CBT aims to reduce hospital readmissions 50%

Smartphone-based CBT aims to help individuals with depression and bipolar disorder, since these are two of the leading causes of disability worldwide. Together, they account for nearly 50% of all morbidity and mortality due to mental and substance use disorders. Besides, patients with affective disorders are more frequently hospitalised than any other patient group.

In 2013, Danish authorities estimated that in Denmark, a country with 5.6 million people, patients with bipolar disorder and depression accounted for 20% of all psychiatric hospitalisations, which is the equivalent of more than 10,800 patients. The cost of these hospitalisations was estimated to be around 87 million Euros per year, which corresponds to 10,800 admissions with an average stay of 20 days at a cost of 400 Euros per day. The most effective treatment for both of these mental disorders includes medication and Cognitive Behavioural Therapy (CBT).


Smartphone-based CBT 

The RADMIS research project, which was granted a budget of 1.3 million Euros by the Danish Innovation Fund, will be done in collaboration with the Mental Health Services of the Capital Region of Denmark (RHP) and the Danish Technical University (DTU).

The project aims to establish clinical evidence that the Monsenso mHealth solution can reduce the number of hospital readmissions of patients with depression and bipolar disorder by 50%. It also seeks to decrease the symptoms and improve the quality of life of outpatients with depression or bipolar disorder receiving smartphone-based CBT.

The multi-disciplinary team involved in the project is comprised of scientific researchers, psychiatrists, psychologists, and computer scientists. This group has already shown promising scientific results with the MONARCA research project.

The use of an intelligent, smartphone-based CBT for the monitoring and treatment for depression and bipolar disorders has never been tried before.

  • The system combines automatic sensing and data collection with customisable self-assessment forms
  • It provides advanced data analysis and forecasting of disease progression, allowing patient and treatment personnel day-to-day assessment, prediction and insight into causes of changes in health state
  • It provides a platform for CBT treatment using innovative multi-media messages delivered ‘in-context’, tracking of medicine administration and compliance, as well as two-way communication between the patient and the clinic

Furthermore, smartphones have never been used in the research and collection of clinical evidence to reduce re-hospitalisation and improve treatment response among patients with depression and bipolar disorder.

After being discharged from the hospital, psychiatric patients undergo a high-risk period in which they are considered to have an increased risk of suicide of 300 times more during the first week and a high-risk of readmission. In fact, psychiatric patients are often afraid to leave the hospital, feeling alone and overwhelmed with the prospect of an appointment with a clinician in one or more months ahead.

A pilot study in Copenhagen involving 29 recently-discharged patients revealed the importance of continued contact with a care provider. In this study, patients used a daily computer system to self-monitor.

The study revealed that daily contact with a nurse using the bidirectional feedback system combined with a smartphone-based identifier of early-warning signs lowers the risk of relapse of depressive and (hypo-) manic symptoms. The pilot study also revealed that the incidence of suicide attempts and the rate of re-hospitalisation decreased.

The hypotheses to be investigated by the project

This project investigates two clinical questions related to the treatment of patients and one technical question related to online learning forecast systems:

  1. Can the risk and duration of psychiatric re-hospitalisation be reduced by using smartphone-based treatment?
  2. Can depressive and manic symptoms, psycho-social function, recovery, empowerment and quality of life be improved by using smartphone-based treatment?
  3. Can machine learning methodology, that runs on a smartphone app and adapts to data as it is collected, give users accurate forecasts and feedback on early warning signs of upcoming depression and hypomania/mania?

A bi-weekly workshop with 6-8 users will be conducted with a focus on the design of the features of the smartphone-based treatment system.

The questions will be investigated in two separate RCTs, focusing on the two patient groups (depressive and bipolar patients) with similar designs comparing the use of smartphone-based treatment with standard care. Each patient will be subject to the trial for six months. Recruitment, inclusion criteria and randomisation: 200 patients with recurrent depression and 200 patients with bipolar disorder at one of the five psychiatric centres in RHP. Patients aged 18 to 70 years will be screened with Schedules for Clinical Assessment in Neuropsychiatry (SCAN) to confirm the ICD-10 diagnosis.

Health outcomes:

Primary: Rate of re-hospitalisation and duration of hospitalisations.
Secondary: Severity of depression according to scores on the Hamilton Depression Rating Scale (36) and Young Mania Rating Scale (YMRS) (37) (for bipolar disorder patients only), at a given time point during the 6 month trial period. Functional assessment short test (FAST) (psychosocial function) (38).
Tertiary: Recovery Assessment Scale (39), empowerment according to Rogers empowerment scale (40), the WHO (Five) well-being index (41) and the Verona Satisfaction Scale-Affective Disorder (VSS-A) (42). Assessment of outcomes will be done by researchers blinded to allocation (single blinded).